skip to Main Content

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Adding pegylated recombinant human hyaluronidase (PEGPH20) to modified FOLFIRINOX (mFOLFIRINOX) may negative affect overall survival (OS) among patients with pancreatic cancer, according to research being presented at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California.

Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve OS among patients with metastatic pancreatic adenocarcinoma. For this randomized phase 1b/2 study ( Identifier: NCT01959139), researchers evaluated the safety and efficacy of PEGPH20 with mFOLFIRINOX vs mFOLFIRINOX alone among 138 patients with good performance status and adequate organ function.  Read more . . .

Back To Top